ImmunityBio, Inc.
General ticker "IBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
ImmunityBio, Inc. does not follow the US Stock Market performance with the rate: -3.5%.
Estimated limits based on current volatility of 12.8%: low 3.45$, high 4.47$
Factors to consider:
- Total employees count: 680 (+8.3%) as of 2024
- US accounted for 96.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Single product reliance, High R&D costs, Regulatory and compliance, Manufacturing scale up, Intellectual property risks
- Current price 65.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.67$, 4.48$]
- 2025-12-31 to 2026-12-31 estimated range: [1.21$, 3.33$]
Financial Metrics affecting the IBRX estimates:
- Positive: with PPE of -3.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -21.08 <= 0.04
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term IBRX quotes
Long-term IBRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.24MM | $0.62MM | $14.74MM |
| Operating Expenses | $351.54MM | $362.87MM | $358.93MM |
| Operating Income | $-351.30MM | $-362.25MM | $-344.18MM |
| Non-Operating Income | $-65.99MM | $-221.64MM | $-69.46MM |
| Interest Expense | $63.52MM | $129.20MM | $154.33MM |
| R&D Expense | $248.15MM | $232.37MM | $190.14MM |
| Income(Loss) | $-417.29MM | $-583.89MM | $-413.64MM |
| Taxes | $0.03MM | $-0.04MM | $0.00MM |
| Profit(Loss)* | $-416.57MM | $-583.20MM | $-413.56MM |
| Stockholders Equity | $-447.33MM | $-586.99MM | $-489.10MM |
| Inventory | $0.00MM | $0.00MM | $8.27MM |
| Assets | $362.36MM | $504.45MM | $382.93MM |
| Operating Cash Flow | $-337.51MM | $-366.76MM | $-391.24MM |
| Capital expenditure | $78.16MM | $30.58MM | $6.89MM |
| Investing Cash Flow | $27.30MM | $-30.47MM | $-12.25MM |
| Financing Cash Flow | $233.61MM | $558.34MM | $281.63MM |
| Earnings Per Share** | $-1.04 | $-1.15 | $-0.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.